A citation-based method for searching scientific literature

C Birchmeier, S Sharma, M Wigler. Proc Natl Acad Sci U S A 1987
Times Cited: 157







List of co-cited articles
1033 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
Klarisa Rikova, Ailan Guo, Qingfu Zeng, Anthony Possemato, Jian Yu, Herbert Haack, Julie Nardone, Kimberly Lee, Cynthia Reeves, Yu Li,[...]. Cell 2007
75

ROS1 rearrangements define a unique molecular class of lung cancers.
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M Lovly, Nerina T McDonald, Pierre P Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang,[...]. J Clin Oncol 2012
73

RET, ROS1 and ALK fusions in lung cancer.
Kengo Takeuchi, Manabu Soda, Yuki Togashi, Ritsuro Suzuki, Seiji Sakata, Satoko Hatano, Reimi Asaka, Wakako Hamanaka, Hironori Ninomiya, Hirofumi Uehara,[...]. Nat Med 2012
896
53

Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma.
Ting-Lei Gu, Xiaxing Deng, Feizhou Huang, Meghan Tucker, Katherine Crosby, Victoria Rimkunas, Yi Wang, Gang Deng, Lei Zhu, Zhiping Tan,[...]. PLoS One 2011
221
50

Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
44

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
Kurtis D Davies, Anh T Le, Mariana F Theodoro, Margaret C Skokan, Dara L Aisner, Eamon M Berge, Luigi M Terracciano, Federico Cappuzzo, Matteo Incarbone, Massimo Roncalli,[...]. Clin Cancer Res 2012
300
43

Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21).
Alain Charest, Keara Lane, Kevin McMahon, Julie Park, Elizabeth Preisinger, Helen Conroy, David Housman. Genes Chromosomes Cancer 2003
144
42

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Manabu Soda, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka,[...]. Nature 2007
37

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Eunice L Kwak, Yung-Jue Bang, D Ross Camidge, Alice T Shaw, Benjamin Solomon, Robert G Maki, Sai-Hong I Ou, Bruce J Dezube, Pasi A Jänne, Daniel B Costa,[...]. N Engl J Med 2010
35

Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
Victoria M Rimkunas, Katherine E Crosby, Daiqiang Li, Yerong Hu, Meghan E Kelly, Ting-Lei Gu, Jennifer S Mack, Matthew R Silver, Xinmin Zhou, Herbert Haack. Clin Cancer Res 2012
203
35

ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice.
Al Charest, Erik W Wilker, Margaret E McLaughlin, Keara Lane, Ram Gowda, Shanie Coven, Kevin McMahon, Steven Kovach, Yun Feng, Michael B Yaffe,[...]. Cancer Res 2006
108
30

Molecular pathways: ROS1 fusion proteins in cancer.
Kurtis D Davies, Robert C Doebele. Clin Cancer Res 2013
219
30

Characterization of ROS1 cDNA from a human glioblastoma cell line.
C Birchmeier, K O'Neill, M Riggs, M Wigler. Proc Natl Acad Sci U S A 1990
93
30

The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer.
Jaime Acquaviva, Ricky Wong, Al Charest. Biochim Biophys Acta 2009
129
27

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
Julien Mazières, Gérard Zalcman, Lucio Crinò, Pamela Biondani, Fabrice Barlesi, Thomas Filleron, Anne-Marie C Dingemans, Hervé Léna, Isabelle Monnet, Sacha I Rothschild,[...]. J Clin Oncol 2015
247
27

Acquired resistance to crizotinib from a mutation in CD74-ROS1.
Mark M Awad, Ryohei Katayama, Michele McTigue, Wei Liu, Ya-Li Deng, Alexei Brooun, Luc Friboulet, Donghui Huang, Matthew D Falk, Sergei Timofeevski,[...]. N Engl J Med 2013
242
25

Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours.
Ashley H Birch, Suzanna L Arcand, Kathleen K Oros, Kurosh Rahimi, A Kevin Watters, Diane Provencher, Celia M Greenwood, Anne-Marie Mes-Masson, Patricia N Tonin. PLoS One 2011
71
33

Identification of ROS1 rearrangement in gastric adenocarcinoma.
Jeeyun Lee, Seung Eun Lee, So Young Kang, In-Gu Do, Sujin Lee, Sang Yun Ha, Jeonghee Cho, Won Ki Kang, Jiryeon Jang, Sai-Hong Ignatius Ou,[...]. Cancer 2013
89
26

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinó, Myung-Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin J Solomon, Fiona Blackhall,[...]. N Engl J Med 2013
23

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Tony S Mok, Yi-Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose,[...]. N Engl J Med 2009
21

Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma.
Alan Charest, Vicky Kheifets, Julie Park, Keara Lane, Kevin McMahon, Cathy L Nutt, David Housman. Proc Natl Acad Sci U S A 2003
64
31

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J Guillermo Paez, Pasi A Jänne, Jeffrey C Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J Kaye, Neal Lindeman, Titus J Boggon,[...]. Science 2004
20

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska,[...]. N Engl J Med 2004
20

KIF5B-RET fusions in lung adenocarcinoma.
Takashi Kohno, Hitoshi Ichikawa, Yasushi Totoki, Kazuki Yasuda, Masaki Hiramoto, Takao Nammo, Hiromi Sakamoto, Koji Tsuta, Koh Furuta, Yoko Shimada,[...]. Nat Med 2012
570
20

Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
Justin F Gainor, Alice T Shaw. Oncologist 2013
229
20

Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.
Yoshiyuki Suehara, Maria Arcila, Lu Wang, Adnan Hasanovic, Daphne Ang, Tatsuo Ito, Yuki Kimura, Alexander Drilon, Udayan Guha, Valerie Rusch,[...]. Clin Cancer Res 2012
133
19

The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
H R Kim, S M Lim, H J Kim, S K Hwang, J K Park, E Shin, M K Bae, S-H I Ou, J Wang, S S Jewell,[...]. Ann Oncol 2013
82
23

Kinase fusions are frequent in Spitz tumours and spitzoid melanomas.
Thomas Wiesner, Jie He, Roman Yelensky, Rosaura Esteve-Puig, Thomas Botton, Iwei Yeh, Doron Lipson, Geoff Otto, Kristina Brennan, Rajmohan Murali,[...]. Nat Commun 2014
368
19

The transcriptional landscape and mutational profile of lung adenocarcinoma.
Jeong-Sun Seo, Young Seok Ju, Won-Chul Lee, Jong-Yeon Shin, June Koo Lee, Thomas Bleazard, Junho Lee, Yoo Jin Jung, Jung-Oh Kim, Jung-Young Shin,[...]. Genome Res 2012
406
18

The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation.
Hyun Jung Jun, Hannah Johnson, Roderick T Bronson, Sebastien de Feraudy, Forest White, Alain Charest. Cancer Res 2012
66
27

Mouse model for ROS1-rearranged lung cancer.
Yasuhito Arai, Yasushi Totoki, Hiroyuki Takahashi, Hiromi Nakamura, Natsuko Hama, Takashi Kohno, Koji Tsuta, Akihiko Yoshida, Hisao Asamura, Michihiro Mutoh,[...]. PLoS One 2013
46
39

ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases.
Akihiko Yoshida, Takashi Kohno, Koji Tsuta, Susumu Wakai, Yasuhito Arai, Yoko Shimada, Hisao Asamura, Koh Furuta, Tatsuhiro Shibata, Hitoshi Tsuda. Am J Surg Pathol 2013
116
17

ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.
Lynette M Sholl, Heather Sun, Mohit Butaney, Chengsheng Zhang, Charles Lee, Pasi A Jänne, Scott J Rodig. Am J Surg Pathol 2013
125
17

Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers.
Chenguang Li, Rong Fang, Yihua Sun, Xiangkun Han, Fei Li, Bin Gao, A John Iafrate, Xin-Yuan Liu, William Pao, Haiquan Chen,[...]. PLoS One 2011
157
16

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
Doron Lipson, Marzia Capelletti, Roman Yelensky, Geoff Otto, Alex Parker, Mirna Jarosz, John A Curran, Sohail Balasubramanian, Troy Bloom, Kristina W Brennan,[...]. Nat Med 2012
615
16

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.
S W Morris, M N Kirstein, M B Valentine, K G Dittmer, D N Shapiro, D L Saltman, A T Look. Science 1994
16

Genomic landscape of non-small cell lung cancer in smokers and never-smokers.
Ramaswamy Govindan, Li Ding, Malachi Griffith, Janakiraman Subramanian, Nathan D Dees, Krishna L Kanchi, Christopher A Maher, Robert Fulton, Lucinda Fulton, John Wallis,[...]. Cell 2012
808
16

Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.
Hiroyuki Yasuda, Lorena L de Figueiredo-Pontes, Susumu Kobayashi, Daniel B Costa. J Thorac Oncol 2012
111
16

RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.
Rui Wang, Haichuan Hu, Yunjian Pan, Yuan Li, Ting Ye, Chenguang Li, Xiaoyang Luo, Lei Wang, Hang Li, Yang Zhang,[...]. J Clin Oncol 2012
347
16

On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Lénaïg Mescam-Mancini, Sylvie Lantuéjoul, Denis Moro-Sibilot, Isabelle Rouquette, Pierre-Jean Souquet, Clarisse Audigier-Valette, Jean-Christophe Sabourin, Chantal Decroisette, Linda Sakhri, Elisabeth Brambilla,[...]. Lung Cancer 2014
93
17

ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
Dara L Aisner, Teresa T Nguyen, Diego D Paskulin, Anh T Le, Jerry Haney, Nathan Schulte, Fiona Chionh, Jenny Hardingham, John Mariadason, Niall Tebbutt,[...]. Mol Cancer Res 2014
87
18

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.
Ultan McDermott, A John Iafrate, Nathanael S Gray, Toshi Shioda, Marie Classon, Shyamala Maheswaran, Wenjun Zhou, Hwan Geun Choi, Shannon L Smith, Lori Dowell,[...]. Cancer Res 2008
326
15

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Alice T Shaw, Beow Y Yeap, Mari Mino-Kenudson, Subba R Digumarthy, Daniel B Costa, Rebecca S Heist, Benjamin Solomon, Hannah Stubbs, Sonal Admane, Ultan McDermott,[...]. J Clin Oncol 2009
15

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.
A Vaishnavi, M Capelletti, A T Le, S Kako, M Butaney, D Ercan, S Mahale, K D Davies, D L Aisner, A B Pilling,[...]. Nat Med 2013
395
15

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Benjamin J Solomon, Tony Mok, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari,[...]. N Engl J Med 2014
15

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell, Enric Carcereny, Radj Gervais, Alain Vergnenegre, Bartomeu Massuti, Enriqueta Felip, Ramon Palmero, Ramon Garcia-Gomez, Cinta Pallares, Jose Miguel Sanchez,[...]. Lancet Oncol 2012
14

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
D Ross Camidge, Yung-Jue Bang, Eunice L Kwak, A John Iafrate, Marileila Varella-Garcia, Stephen B Fox, Gregory J Riely, Benjamin Solomon, Sai-Hong I Ou, Dong-Wan Kim,[...]. Lancet Oncol 2012
930
14

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.
Kurtis D Davies, Sakshi Mahale, David P Astling, Dara L Aisner, Anh T Le, Trista K Hinz, Aria Vaishnavi, Paul A Bunn, Lynn E Heasley, Aik-Choon Tan,[...]. PLoS One 2013
84
16

Ceritinib in ALK-rearranged non-small-cell lung cancer.
Alice T Shaw, Dong-Wan Kim, Ranee Mehra, Daniel S W Tan, Enriqueta Felip, Laura Q M Chow, D Ross Camidge, Johan Vansteenkiste, Sunil Sharma, Tommaso De Pas,[...]. N Engl J Med 2014
14

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Helen Y Zou, Qiuhua Li, Lars D Engstrom, Melissa West, Vicky Appleman, Katy A Wong, Michele McTigue, Ya-Li Deng, Wei Liu, Alexei Brooun,[...]. Proc Natl Acad Sci U S A 2015
159
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.